WELLINGTON MANAGEMENT CO LLP 13D and 13G filings for Iovance Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-06 3:00 pm Sale |
2022-12-30 | 13G | Iovance Biotherapeutics, Inc. IOVA |
WELLINGTON MANAGEMENT CO LLP | 421,610 0.270% |
-9,162,472 (-95.60%) |
Filing |
| 2022-02-04 09:27 am Purchase |
2021-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA |
WELLINGTON MANAGEMENT CO LLP | 9,584,082 6.110% |
9,584,082 (New Position) |
Filing |